Phase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancer

Clinical Cancer Research

Volumn 7, Issue 5, 2001, Pages 1198-1203

  Logothetis, Christopher J ^a   Wu, Kenneth K ^a   Finn, Laury D ^a   Daliani, Danai ^a   Figg, William ^b   Ghaddar, Habib ^a   Gutterman, Jordan U ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANGIOGENESIS INHIBITOR; FUMAGILLOL CHLOROACETYLCARBAMATE;

ADULT; AGED; AGITATION; ANESTHESIA; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; BODY SURFACE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG INFUSION; DRUG RESPONSE; GAIT DISORDER; HUMAN; MALE; MAXIMUM TOLERATED DOSE; NEUROLOGIC DISEASE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER;

AGED; ANDROGENS; ANGIOGENESIS INHIBITORS; BLOOD GLUCOSE; BONE AND BONES; COMMUNICABLE DISEASES; CYCLOHEXANES; DIGESTIVE SYSTEM; FIBROBLAST GROWTH FACTORS; HUMANS; KINETICS; LIVER; MALE; MIDDLE AGED; PAIN; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SESQUITERPENES; THROMBOMODULIN;

EID: 0034901968     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. What is the evidence that tumors are angiogenesis dependent?
2. Tumor angiogenesis: Therapeutic implications
3. Frequence des metastases viscerales chez les souris cancereuses apres ablation chirurgicale de leur tumeur
4. Suppression of solid tumor growth by immunoneutralizing monoclonal antibody against human basic fibroblast growth factor
5. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth
6. Inhibition of tumor growth and metastasis of rodent tumors by the angiogenesis inhibitor O-(chloroacetyl-carbamoyl) fumagillol (TNP-470; AGM-1470)
7. Angiogenesis and breast cancer
8. Significance of tumor angiogenesis in clinically localized prostate carcinoma treated with external beam radiotherapy
9. Inhibition of angiogenesis
10. Plasma thrombomodulin as a marker of vascular disorders in thrombotic thrombocytopenic purpura and disseminated intravascular coagulation
11. Increased levels of plasma thrombomodulin in chronic myelogenous leukemia
12. Increased levels of soluble adhesion molecules in type 2 diabetes mellitus are independent of glycemic control
13. Circulating endothelial cell/leukocyte adhesion molecules in atherosclerosis